Presatovir

Presatovir (GS-5806) is an antiviral drug which was developed as a treatment for respiratory syncytial virus.[1][2] It acts as a fusion inhibitor, and has shown promising results in Phase II clinical trials.[3][4]

Presatovir
Clinical data
Trade namesPresatovir
Legal status
Legal status
Identifiers
IUPAC name
  • N-[2-[(2S)-2-[5-[(3S)-3-aminopyrrolidin-1-yl]-6-methylpyrazolo[1,5-a]pyrimidin-2-yl]piperidine-1-carbonyl]-4-chlorophenyl]methanesulfonamide
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC24H30ClN7O3S
Molar mass532.1 g·mol−1
3D model (JSmol)
SMILES
  • CC1=CN2C(=CC(=N2)[C@@H]3CCCCN3C(=O)C4=C(C=CC(=C4)Cl)NS(=O)(=O)C)N=C1N5CC[C@@H](C5)N
InChI
  • InChI=1S/C24H30ClN7O3S/c1-15-13-32-22(27-23(15)30-10-8-17(26)14-30)12-20(28-32)21-5-3-4-9-31(21)24(33)18-11-16(25)6-7-19(18)29-36(2,34)35/h6-7,11-13,17,21,29H,3-5,8-10,14,26H2,1-2H3/t17-,21-/m0/s1
  • Key:GOFXWTVKPWJNGD-UWJYYQICSA-N

See also

References
  1. Mackman RL, Sangi M, Sperandio D, Parrish JP, Eisenberg E, Perron M, et al. (February 2015). "Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study". Journal of Medicinal Chemistry. 58 (4): 1630–1643. doi:10.1021/jm5017768. PMID 25574686.
  2. Yamaguchi-Sasaki T, Tamura Y, Ogata Y, Kawaguchi T, Kurosaka J, Sugaya Y, et al. (2020). "Design and Synthesis of 2-(1-Alkylaminoalkyl)pyrazolo[1,5-a]pyrimidines as New Respiratory Syncytial Virus Fusion Protein Inhibitors". Chemical & Pharmaceutical Bulletin. 68 (4): 345–362. doi:10.1248/cpb.c19-00895. PMID 32238652.
  3. Marty FM, Chemaly RF, Mullane KM, Lee DG, Hirsch HH, Small CB, et al. (December 2019). "A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract". Clinical Infectious Diseases. doi:10.1093/cid/ciz1167. PMID 31915807.
  4. Stray K, Perron M, Porter DP, Anderson F, Lewis SA, Perry J, et al. (January 2020). "Drug resistance assessment following administration of RSV fusion inhibitor presatovir to participants experimentally infected with respiratory syncytial virus". The Journal of Infectious Diseases. doi:10.1093/infdis/jiaa028. PMID 31971597.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.